O Y S T E R P O I N T M A R I N A P L A Z AOffice Lease • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations • California
AMENDMENT NO. 3 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment No. 3”) to LICENSING AND ASSIGNMENT AGREEMENT, made and entered into the 6th day of October, 2017 (“Amendment No. 3 Effective Date”) by and between Satsuma Pharmaceuticals, Inc., having its principal place of business at 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA (“Company”) and Shin Nippon Biomedical Laboratories, Ltd., having its principal place of business at 2438, Miyanoura-cho, Kagoshima-shi, Kagoshima-ken, Japan (“SNBL”). Company and SNBL are collectively the “Parties”.
AMENDMENT NO. 2 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of April 27, 2017 (“Amendment No. 2 Effective Date”)
Amendment to Offer LetterOffer Letter Amendment • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to the Offer Letter from Satsuma Pharmaceuticals, Inc. (the “Company”) to John A. Kollins dated as of June 17, 2016 (this “Amendment”), is effective upon the Closing of the Qualified Financing of the Company (as defined herein) (the “Effective Date”).
